Clinical trial · Interventional
An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients
NCT00309101CI-TRIAL-00002353completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to investigate the efficacy and safety for steroid resistant, non-thymectomized MG patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tacrolimus | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1. tacrolimus
- interventionNames
- Drug: tacrolimus
Primary outcomes (1)
- measure
- Improvement of clinical symptoms
- timeFrame
- 28 Weeks
Secondary outcomes (1)
- measure
- Improvement of daily activity
- timeFrame
- 28 Weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 64 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically diagnosed as myasthenia gravis * Those whose MG symptoms are not controlled by the treatment with prednisone Exclusion Criteria: * Those who had undergone thymectomy
References
Publications (0)
Data not yet available
No reference posted for this study.